Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Efstathios Kastritis, MD, Evangelos Terpos, MDPhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, Eirini Katodritou, MD, Elena Rivolti, MD, Marie-Christine Kyrtsonis, MD, Maria Gavriatopoulou, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, MD, Nikolaos Kanellias, MD, Magdalini Migkou, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-140322

Published: 2020

Journal Articles

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Despina Fotiou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Foteini Theodorakakou, MD, Maria Roussou, MD, Evangelos Terpos, MD PhD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-136248

Published: 2020

Journal Articles

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, MD, Maria Roussou, MD, Eftathios Kastritis, Alexandra Margeli, PhD, Evangelos Eleutherakis-Papaiakovou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Gerasimos-Petros Papassotiriou, PhD, Despina Fotiou, MD, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Erasmia Psimenou, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 1877.

https://doi.org/10.1182/blood-2019-123912

Published: 2019

Journal Articles

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Evangelos Terpos, MD PhD, Ioannis V. Kostopoulos, Aristea-Maria Papanota, MD, Konstantinos Papadimitriou, BSc, Panagiotis Malandrakis, MD, Paraskevi Micheli, BSc, Ioannis Ntanasis-Stathopoulos, MD, Despina Fotiou, MD, Andreas Metousis, BSc, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Ourania E. Tsitsilonis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4338.

https://doi.org/10.1182/blood-2019-127989

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Blood (2018) 132 (Supplement 1): 1966.

https://doi.org/10.1182/blood-2018-99-112851

Published: 2018

Journal Articles

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Evangelos Terpos, MD PhD, Maria Roussou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Despina Fotiou, MD, Dimitrios C. Ziogas, MD, Aristea-Maria Papanota, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Efstathios Kastritis, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2018-99-113108

Published: 2018

NARROW

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only